The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer

Cancer

Volumn 120, Issue 11, 2014, Pages 1656-1662

  Abern, Michael R ^a   Terris, Martha K ^b,c   Aronson, William J ^d,e   Kane, Christopher J ^f   Amling, Christopher L ^g   Cooperberg, Matthew R ^h,i   Freedland, Stephen J ^j,k  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^j DURHAM VA MEDICAL CENTER   (United States)

^k DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

pathology; prostatectomy; prostatic neoplasms; treatment outcome

Indexed keywords

ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; BODY MASS; CANCER STAGING; CANCER SURVIVAL; DISEASE SPECIFIC SURVIVAL; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SURVIVAL RATE; SURVIVAL TIME;

PATHOLOGY; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 84901370105     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28647     Document Type: Article

References (22)

1. Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G,. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol. 2008; 15: 3866-3871.
2. Shao YH, Demissie K, Shih W, et al. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst. 2009; 101: 1280-1283.
3. Bastian PJ, Boorjian SA, Bossi A, et al. High-risk prostate cancer: from definition to contemporary management. Eur Urol. 2012; 61: 1096-1106.
4. Cooperberg MR, Cowan J, Broering JM, Carroll PR,. High-risk prostate cancer in the United States, 1990-2007. World J Urol. 2008; 26: 211-218.
5. Epstein JI, Feng Z, Trock BJ, Pierorazio PM,. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol. 2012; 61: 1019-1024.
6. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H,. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 2005; 95: 751-756.
7. Cooperberg MR, Broering JM, Carroll PR,. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010; 28: 1117-1123.
8. Jason PF, Gray RJ,. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94: 496-509.
9. Briganti A, Spahn M, Joniau S, et al. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis. Eur Urol. 2013; 63: 693-701.
10. Akre O, Garmo H, Adolfsson J, Lambe M, Bratt O, Stattin P,. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden. Eur Urol. 2011; 60: 554-563.
11. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012; 367: 203-213.
12. Bastian PJ, Gonzalgo ML, Aronson WJ, et al. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer. 2006; 107: 1265-1272.
13. Freedland SJ, Partin AW, Humphreys EB, Mangold LA, Walsh PC,. Radical prostatectomy for clinical stage T3a disease. Cancer. 2007; 109: 1273-1278.
14. Inman BA, Davies JD, Rangel LJ, et al. Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level ≥ 50 ng/mL. Cancer. 2008; 113: 1544-1551.
15. Loeb S, Schaeffer EM, Trock BJ, Epstein JI, Humphreys EB, Walsh PC,. What are the outcomes of radical prostatectomy for high-risk prostate cancer? Urology. 2010; 76: 710-714.
16. Ploussard G, Masson-Lecomte A, Beauval JB, et al. Prostate Cancer Committee of the French Association of Urology. Radical prostatectomy for high-risk prostate cancer defined by preoperative criteria: oncologic follow-up in national multicenter study in 813 patients and assessment of easy-to-use prognostic substratification. Urology. 2011; 78: 607-613.
17. Spahn M, Joniau S, Gontero P, et al. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng&so;ml: a European multi-institutional study of 712 patients. Eur Urol. 2010; 58: 1-7; discussion 10-11.
18. Boorjian SA, Karnes RJ, Viterbo R, et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. 2011; 117: 2883-2891.
19. Stephenson AJ, Kattan MW, Eastham JA, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol. 2009; 27: 4300-4305.
20. Kattan MW, Eastham JA, Stapleton AMF, Wheeler TM, Scardino PT,. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998; 90: 766-771.
21. Eifler JB, Feng Z, Lin BM, et al. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int. 2013; 111: 22-29
22. Swanson GP, Thompson IM, Tangen C, et al. Update of SWOG 8794: adjuvant radiotherapy for pT3 prostate cancer improves metastasis free survival. Int J Radiat Oncol Biol Phys. 2008; 72: S31.